Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Healthcare Medical Devices
Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real... see more

Recent & Breaking News (TSXV:ADK)

DIAGNOS Announces Cross-listing of its Common Shares on the Frankfurt Stock Exchange

GlobeNewswire 10 days ago

DIAGNOS Announces Closing of Private Placement

GlobeNewswire October 25, 2024

DIAGNOS Announces the Engagement of Market Maker Consultant

GlobeNewswire October 17, 2024

DIAGNOS Announces Grant of Stock Options

GlobeNewswire October 3, 2024

DIAGNOS Announces Voting Results of Meeting of Shareholders

GlobeNewswire September 26, 2024

DIAGNOS Announces Variation in One Insider Ownership

GlobeNewswire September 23, 2024

DIAGNOS Announces Closing of Private Placement

GlobeNewswire September 20, 2024

DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders

GlobeNewswire August 22, 2024

DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada

GlobeNewswire August 20, 2024

DIAGNOS Announces Closing of Second and Final Tranche of Private Placement

GlobeNewswire June 5, 2024

DIAGNOS celebrates the launch of Labtician's new screening service for diabetic retinopathy in Ontario and renews its distribution agreement

GlobeNewswire May 21, 2024

DIAGNOS Announces Closing of First Tranche of Private Placement

GlobeNewswire May 9, 2024

DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024

GlobeNewswire May 6, 2024

DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification

GlobeNewswire April 16, 2024

DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th

GlobeNewswire April 9, 2024

DIAGNOS Announces Grant of Stock Options

GlobeNewswire April 3, 2024

DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors

GlobeNewswire April 2, 2024

DIAGNOS Announces Closing of Second and Final Tranche of Private Placement

GlobeNewswire March 22, 2024

DIAGNOS Announces Grant of Stock Options

GlobeNewswire March 4, 2024

DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors

GlobeNewswire February 29, 2024